Qiming Venture Partners

Qiming Venture Partners' portfolio company Antengene (SEHK:6996) announced that recent reports from official channels indicate that in the company's Phase 1/2 CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate), an elderly patient with advanced gastric cancer who has progressed on multiple lines of chemotherapy, immunotherapy, and targeted therapy despite extensive metastases achieved a complete response (CR) following ATG-022 monotherapy. The patient's tumor-free status was confirmed by PET/CT in May 2025. This achievement of a CR in this elderly gastric cancer patient is extremely encouraging, highlighting the therapeutic potential of ATG-022 as a novel ADC therapy. Importantly, this is not the only CR observed in the ongoing study. To date, three CR cases have been observed, including patients from both the Chinese Mainland and Australia. #ATG022 #AntibodyDrugConjugate #GastricCancer #OncologyResearch #CancerTherapy #ClinicalTrials #BiotechInnovation #PrecisionMedicine #CancerTreatment #QimingPortfolio #QimingHealthcare

Tony Han, Founder and CEO of Qiming Venture Partners' portfolio company WeRide (NASDAQ:WRD), recently joined CNBC's China Connection to discuss the company's global growth and technological breakthroughs in autonomous driving. "We focus on developing the best technology for autonomous driving and keep on doing international expansion. So far, WeRide is the only company in this world that has autonomous driving products with a driverless permit in six countries. So we will keep our competitive edge. And we have big market potential," said Tony Han. #AutonomousDriving #Robotaxi #MobilityInnovation #GlobalExpansion #CNBC #SmartMobility #AVTechnology #QimingPortfolio #QimingTechnology

At the 38th Stop TB Partnership Board Meeting, KNCV Nigeria presented Qiming Venture Partners' portfolio company Pluslife's MiniDock platform as part of its pipeline of diagnostic tools under consideration for programmatic use. Engineered for decentralized molecular testing, MiniDock is designed to meet the needs of low-resource settings. With a hands-on time of under 2 minutes and a run time of just 5–25 minutes, the platform supports both tongue swabs and sputum samples, making it highly adaptable for rapid, on-site tuberculosis testing and other urgent diagnostic needs. #GlobalHealth #Diagnostics #TBDetection #MolecularTesting #InnovationInHealth #DecentralizedTesting #QimingPortfolio #QimingHealthcare

HyperStrong (SHSE:688411), a Qiming Venture Partners' portfolio company, announced that its core product, the 314Ah-1P416S battery pack system, has successfully passed certification under China's national safety standard GB 44240-2024—"Secondary Lithium Cells and Batteries Used in Electrical Energy Storage Systems—Safety Requirements." Certified by the National Quality Inspection and Testing Center for Energy Storage and Power Batteries, HyperStrong is among the first companies in the industry to meet the rigorous requirements of this standard. The system demonstrated exceptional performance across key dimensions, including durability of critical components, stability under extreme conditions, thermal abuse safety, and real-time responsiveness of hardware and software. #EnergyStorage #BatteryTechnology #LithiumBatteries #SafetyStandards #Innovation #QimingPortfolio #QimingTechnology

Insight Lifetech Co., Ltd. , a Qiming Venture Partners' portfolio company, has received Class II medical device registration approval from the Guangdong Medical Products Administration in China for its innovative iFlowX™ digital pressure pump. As the first intelligent digital pressure pump of its kind, iFlowX™ represents a significant step forward in the digitalization and intelligent upgrade of essential consumables. Powered by advanced algorithms, the device can detect calcification fractures in real time and issue visual alerts to enhance procedural safety and improve patient outcomes. Once stable pressure is detected, the system automatically initiates timing to provide precise guidance for drug-coated balloon inflation. It also records and displays the last three sets of inflation peak pressures and durations, allowing clinicians to quickly review historical data. #MedicalDevices #HealthcareInnovation #SmartSurgery #iFlowX #QimingPortfolio #QimingHealthcare

Qiming Venture Partners' portfolio company Yuanbao Inc. (NASDAQ: YB) recently donated RMB 100,000 worth of critical medical equipment to Zhuozi County in Ulanqab, Inner Mongolia Autonomous Region. The donation included three defibrillator monitors and two semi-automated AEDs, addressing an urgent need for life-saving devices in the region. As user-friendly emergency tools, AEDs play a crucial role in improving survival rates from sudden cardiac arrest. The donated equipment has been allocated by the local Red Cross Society to key departments at the County People's Hospital and to grassroots police stations in local townships under the County Public Security Bureau. #SocialImpact #HealthcareAccess #EmergencyCare #PublicHealth #AED #Defibrillator #CorporateResponsibility #QimingPortfolio #ESG

52TOYS, a portfolio company of Qiming Venture Partners, has officially opened its seventh branded store in Thailand, located in Bangkok's Seacon Square Srinagarindra. The new store features a dedicated experience zone for CiCiLu, an original character introduced at the Thailand Toy Expo (TTE) in April. Set in a post-apocalyptic world submerged by the sea, CiCiLu is a messenger who sails between islands, delivering wishes, secrets, and memories. Since entering the Thai market in 2019, 52TOYS has continued to engage local consumers with its innovative lineup of original IP toys. The opening of the Seacon Square Srinagarindra store further strengthens the brand's presence in Thailand and deepens its connection with collectors. #IPCreation #CiCiLu #ToyIndustry #ThailandRetail #PopCulture #ConsumerEngagement #QimingPortfolio

The Chinese University of Hong Kong (CUHK) officially announced that its multidisciplinary research team, in collaboration with Cornerstone Robotics, a portfolio company of Qiming Venture Partners, has successfully developed the world's first embodied intelligence platform for multitask surgical automation. The team also completed the world's first clinical validation of autonomous surgery using this platform on Cornerstone Robotics' self-developed Sentire® Endoscopic Surgical System. The research paper, titled "Surgical Embodied Intelligence for Generalized Task Autonomy in Laparoscopic Robot-assisted Surgery", has been published in Science Robotics, a prestigious research journal in the field of robotics and a flagship publication under the Science family. This marks the first successful in vivo animal testing using a Chinese-developed laparoscopic surgical robot equipped with AI-powered embodied intelligence, validating its multitask autonomy and human-robot collaboration capabilities. It demonstrates the generalisability of the algorithms and the system's clinical feasibility, paving the way for a future of smarter, more collaborative, and more accessible robotic surgery. #EmbodiedIntelligence #SurgicalRobotics #AutonomousSurgery #AIinHealthcare #RobotAssistedSurgery #MedicalInnovation #ClinicalResearch #ScienceRobotics #QimingPortfolio #QimingHealthcare Read More: https://xmrrwallet.com/cmx.plnkd.in/g3u6VkRq

With the technical expertise of Qiming Venture Partners' portfolio company Goodwill (SHSE:688246), Linyi Central Hospital in Shandong Province has launched an integrated hospital-wide indicator analysis platform based on a robust data middle platform, significantly improving hospital management efficiency. By leveraging Goodwill's data platform, the hospital has established a comprehensive data governance system covering all critical sources such as HIS, EMR, and PACS, ensuring data consistency and accuracy across systems. A well-defined governance framework guides every stage from data collection and cleansing to integration and storage with strict standards and processes in place. To date, the platform connects 40 data sources, collecting data from 383 tables and over 1.6 billion records. Its clean data lake incorporates 143 data standards and has successfully governed 648 million records. #HealthcareInnovation #DataGovernance #HospitalManagement #DigitalHealth #HealthIT #QimingPortfolio #QimingHealthcare

Hesai Technology (NASDAQ:HSAI), a portfolio company of Qiming Venture Partners, has announced a strategic partnership with Vbot, China's first consumer-grade embodied intelligence company. Through the deep integration of lidar and AI, the collaboration aims to advance robotic perception and interaction, paving the way for the commercialization of embodied intelligence and the launch of the industry's first intelligent companion robot. As AI and robotics technologies continue to converge, lidar is expanding beyond autonomous driving into broader robotic applications. The partnership between Hesai Technology and Vbot marks a key milestone in building a closed-loop system of perception, decision-making, and execution, unlocking new value for intelligent robots in real-world environments. #EmbodiedAI #Robotics #LidarTechnology #AIInnovation #SmartRobots #TechPartnership #QimingPortfolio #QimingTechnology